DOCSLIB.ORG

CD24 for Cardiovascular Researchers: a Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CD24 for Cardiovascular Researchers: a Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development Journal of Personalized Medicine Review CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development Eyal Sagiv * and Michael A. Portman Division of Pediatric Cardiology, Seattle Children’s Hospital and the University of Washington School of Medicine, Seattle, WA 98105, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-206-987-6916; Fax: +1-206-987-3839 Abstract: The study of the membrane protein, CD24, and its emerging role in major disease processes, has made a huge leap forward in the past two decades. It appears to have various key roles in oncogenesis, tumor progression and metastasis, stem cell maintenance and immune modulation. First described in the 1980s as the homologous human protein to the mouse HSA (Heat Stable Anti- gen), it was reported as a surface marker in developing hematopoietic cell lines. The later discovery of its overexpression in a large number of human neoplasms, lead cancer researchers to discover its various active roles in critical checkpoints during cancer development and progression. Targeting CD24 in directed drug development showed promising results in cancer treatment. More recently, the chimeric CD24-Fc protein has shown exciting results in clinical trials as a specific modulator of auto-inflammatory syndromes. This report is aimed to summarize the relevant literature on CD24 and tie it together with recent advancements in cardiovascular research. We hypothesize that CD24 is a promising focus of research in the understanding of cardiovascular disease processes and the Citation: Sagiv, E.; Portman, M.A. development of novel biological therapies. CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Keywords: CD24; dilated cardiomyopathy; vasculitis; immune modulator; multisystem inflamma- Marker of Stem Cells and Target for tory syndrome in children (MIS-C) Drug Development. J. Pers. Med. 2021, 11, 260. https://doi.org/ 10.3390/jpm11040260 1. Background Academic Editors: Nadir Arber and CD24 is a membrane protein that is composed of a short peptide backbone with Shiran Shapira no transmembrane domain and is anchored to the membrane by glycosyl-phosphatidyl- inositol (GPI) [1]. It is heavily glycosylated in a pattern that can change between different Received: 15 February 2021 cells, perhaps accounting for its various interactions and roles. The human CD24 gene Accepted: 29 March 2021 Published: 1 April 2021 is located on chromosome 6q21. The initial cloning and mapping of the CD24 gene was challenging due to the presence of homologous areas in the human genome, especially two Publisher’s Note: MDPI stays neutral highly observed sequences in chromosome location 15q21 and Yq11, most likely non-coding with regard to jurisdictional claims in pseudo-genes [2]. The conservation of gene copies in human genome, highly homologous published maps and institutional affil- to its sequences in other species, is suggestive of a functional role with evolutionary 0 iations. significance. The human gene encodes a long mRNA molecule with a relatively long 5 UTR (untranslated region) and a reading frame of 243 base pairs. The 81 amino acids peptide undergoes significant modifications in the endoplasmic reticulum, including cleavage of membrane- directing region and GPI anchor enhancing peptide tail. The mature peptide is a sequence of 31 amino acids of a molecular weight that ranges from 30 to 75 kDa Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. depending on the attached glycans. It is directed through the GPI anchor to be expressed in This article is an open access article lipid-enriched areas that harbor other mucins and signal receptors, known as ‘lipid rafts’ [3]. distributed under the terms and The human CD24 protein was found on the outer cell membrane of multiple cell conditions of the Creative Commons lines [4]. It was initially reported to be expressed in the healthy human in B cell populations Attribution (CC BY) license (https:// during specific phases of maturation and absent on mature plasma cells. It was then shown creativecommons.org/licenses/by/ to be expressed on other immune cells including T cells and dendritic cells, during regula- 4.0/). tory phases of innate immune response [5]. The commercial availability of an anti-CD24 J. Pers. Med. 2021, 11, 260. https://doi.org/10.3390/jpm11040260 https://www.mdpi.com/journal/jpm J. Pers. Med. 2021, 11, 260 2 of 8 monoclonal antibody for tissue staining and the development of microarray expression assays lead to an influx of research work finding CD24 overexpression in various human malignancies [6]. This includes a subset of hematologic malignancies–non-Hodgkin B-cell lymphomas, acute lymphoblastic leukemia (ALL) and high-risk acute myeloid leukemia (AML)–but more abundant in carcinoma tumors, including breast, ovarian, colon, hepato- cellular, prostate, pancreatic, non-small cell lung, bladder and prostate cancers and others. It has no physiologic expression in the healthy adjacent tissues. In the heart, Chen et al. also reported overexpression of CD24 in cardiac adenocarcinoma tissue, but not in the adjacent mucosa [7]. CD24 was found to be expressed at early stages of the malignant transformation, like intestinal polyps [8], and to confer poorer prognosis [9–11]. In vitro and animal models show the significance of CD24 expression in tumor initiation and cell proliferation, drug- resistance, adhesion to vascular endothelium and metastases forma- tion. More recently, CD24 was shown to have an intriguing role in tumor evasion from phagocytosis, hypothesized to act as a ‘don’t eat me signal’ [12]. The functional role in signal pathways and cell communication of a small peptide with no transmembrane domain remains challenging to decipher. Several protein ligands and binding molecules were identified over the years. CD24 can interact with important adhesion molecules, including P-selectin, E-selectin, and L1CAM (CD171) and activate integrins, thus perhaps participating in leukocyte extravasation in inflammation and cancer metastasis. It was more recently shown to bind the immune cell receptors Siglec-5 and Siglec-10 that have an immune- inhibitory role and possibly anti- phagocytic [6]. Intracel- lular pathways were shown to be activated in response to changes in CD24 expression, directly or indirectly, including CXCR-4, Src or PI3K/Akt kinase proto-oncogenes. Di- rected biological therapies that block CD24 are thus studied as promising novel cancer treatment modalities, using monoclonal antibodies, chimeric molecules or siRNA [13–16]. We would suggest that exploring the role of CD24 in cardiovascular disease processes may lead to targeted drug development in our research field as well. 2. CD24 as a Marker for Progenitor Cells and Its Implications for Post-Ischemic Myocardial Regeneration Studied most extensively in the field of cancer research, CD24 is suggested to be a marker for circulating cancer stem cells (CSCs), a small subset of cancer cells that retains differentiation potency and low proliferative profile. CRCs are defined as responsible for tumor initiation, metastases and resistance to most cancer therapies that target cell proliferation. Studying CRCs in breast carcinoma, Al-Hajj et al. suggested that CD44+CD24– identified cells with preserved potency and tumor initiating ability while CD24 expression marks epithelial- to- mesenchymal transition (EMT) [17]. Following their lead, other studies in different cancer types found CD24 expression to be a marker for the CSCs themselves, overexpressed on cells that maintain tumor initiating abilities [18–21]. These findings are of a particular interest to cardiovascular research. The embryonic cellular pathways associated with CSCs are similar to the fingerprint of mesenchymal transition that characterizes cardiac stem cells. CD24+ CSCs were shown to have active Notch pathway signaling and high expression of SOX-2, OCT-4 and NANOG [6,22], accepted descriptors of successful in vitro derivation of cardiac mesenchymal stem cells (MSCs). CD24 overexpression was shown to trigger Notch-1 signaling and induce EMT [23]. Human cardiomyocytes respond to injury by hypertrophy and proliferation of local supportive tissues that lead to scarring rather than regeneration of contractile cells that lack a sufficient ability to proliferate [24]. Pilot studies suggest that direct myocardial injection of MSCs from autologous de-differentiated source may assist in post-ischemic regenera- tion [25]. In children too, using bone-marrow derived MSCs administered intra-coronary to infants with hypoplastic left heart syndrome (HLHS) is trialed with the goal to support recovery and preserve of systolic function in the single right ventricle [26]. Improved and reliable methodologies to identify circulating MSCs or produce them in the lab are studied and new surface markers are in need. In describing a new protocol for deriving MSCs from human embryonic stem cells (hESCs), Lian et al. [27] used gene expression and cell sorting J. Pers. Med. 2021, 11, 260 3 of 8 analysis to prove that CD24 is a reliable marker for pluripotent hESCs. They showed that CD24 expression is eliminated in successful MSC differentiation while continues to be positive on other cell lines that are inaccurately derived from hESCs, and thus it is a valu- able selection marker. Supporting this conclusion, perhaps, Da Sacco et al. [28] identified CD24+ cells in human amniotic fluid to be metanephric progenitor mesenchymal
Load more

Recommended publications
  • Enrichment and Characterization of Two Subgroups of Committed Osteogenic Cells in the Mouse Endosteal Bone Marrow with Expressio
    ne Marro Bo w f R o e l s a e n a r Chang CF et al., J Bone Marrow Res 2014, 2:2 r c u h o J Journal of Bone Marrow Research DOI: 10.4172/2329-8820.1000144 ISSN: 2329-8820 Research Article Open Access Enrichment and Characterization of Two Subgroups of Committed Osteogenic Cells in the Mouse Endosteal Bone Marrow with Expression Levels of CD24 Ching-Fang Chang1,2, Ke-Hsun Hsu1,2, Chia-Ning Shen1,2,3, Chung-Leung Li2,3* and Jean Lu1,2** 1Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan 2Genomics Research Center, Academia Sinica, Taipei, Taiwan 3Institute of Bioscience and Biotechnology, College of Life Sciences, National Taiwan Ocean University, Keelung, Taiwan Abstract Primary osteogenic cells have been known to reside within the CD45-CD31-Ter119-Sca-1- cell fraction, particularly in the CD51+ subpopulation. However, detailed determination of the frequency of osteogenic cells within this Sca-1- cell population remains yet to be determined. In addition, it is not clear that other cell surface markers can be used to further sub-fractionate this Sca-1-CD51+ osteogenic cell population and to define their developmental stages. In this report, both Sca-1-CD24med and Sca-1- CD24-/lo cells have been shown to be two small subsets of the Sca-1-CD51+ cell fraction. These two cell fractions show subtle difference in the expression level of osteogenic marker genes such as Osx and Opn, and in vitro proliferate rate. All these observations suggest that they may be at different developmental stages of osteogenesis.
    [Show full text]
  • Induction of the CD24 Surface Antigen in Primary Undifferentiated Human Adipose Progenitor Cells by the Hedgehog Signaling Pathway
    Article Induction of the CD24 Surface Antigen in Primary Undifferentiated Human Adipose Progenitor Cells by the Hedgehog Signaling Pathway Francesco Muoio 1 , Stefano Panella 1 , Yves Harder 2,3 and Tiziano Tallone 1,* 1 Foundation for Cardiological Research and Education (FCRE), Cardiocentro Ticino, 6807 Taverne, Switzerland; [email protected] (F.M.); [email protected] (S.P.) 2 Department of Plastic, Reconstructive, and Aesthetic Surgery, EOC, 6900 Lugano, Switzerland; [email protected] or [email protected] 3 Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland * Correspondence: [email protected] or [email protected]; Tel.: +41-91-805-3885 Abstract: In the murine model system of adipogenesis, the CD24 cell surface protein represents a valuable marker to label undifferentiated adipose progenitor cells. Indeed, when injected into the residual fat pads of lipodystrophic mice, these CD24 positive cells reconstitute a normal white adipose tissue (WAT) depot. Unluckily, similar studies in humans are rare and incomplete. This is because it is impossible to obtain large numbers of primary CD24 positive human adipose stem cells (hASCs). This study shows that primary hASCs start to express the glycosylphosphatidylinositol (GPI)-anchored CD24 protein when cultured with a chemically defined medium supplemented with molecules that activate the Hedgehog (Hh) signaling pathway. Therefore, this in vitro system may help understand the biology and role in adipogenesis of the CD24-positive hASCs. The induced Citation: Muoio, F.; Panella, S.; cells’ phenotype was studied by flow cytometry, Real-Time Quantitative Polymerase Chain Reaction Harder, Y.; Tallone, T. Induction of the (RT-qPCR) techniques, and their secretion profile.
    [Show full text]
  • Human B Cells Marked by CD24 Expression Immunodeficiency
    Characterization of Lymphocyte Subsets in Patients with Common Variable Immunodeficiency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression This information is current as of September 29, 2021. Marcela Vlková, Eva Fronková, Veronika Kanderová, Ales Janda, Sárka Ruzicková, Jirí Litzman, Anna Sedivá and Tomás Kalina J Immunol 2010; 185:6431-6438; Prepublished online 1 November 2010; Downloaded from doi: 10.4049/jimmunol.0903876 http://www.jimmunol.org/content/185/11/6431 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2010/11/01/jimmunol.090387 Material 6.DC1 References This article cites 34 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/185/11/6431.full#ref-list-1 Why The JI? Submit online. by guest on September 29, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Characterization of Lymphocyte Subsets in Patients with Common Variable Immunodeficiency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression Marcela Vlkova´,* Eva Fronˇkova´,†,‡ Veronika Kanderova´,†,‡ Alesˇ Janda,† Sˇa´rka Ru˚zˇicˇkova´,x Jirˇ´ı Litzman,* Anna Sˇediva´,{ and Toma´sˇ Kalina†,‡ Increased proportions of naive B cell subset and B cells defined as CD27negCD21negCD38neg are frequently found in patients with common variable immunodeficiency (CVID) syndrome.
    [Show full text]
  • Relationship of CD44 CD24 Breast Cancer Stem Cells and Axillary Lymph Node Metastasis
    Wei et al. Journal of Translational Medicine 2012, 10(Suppl 1):S6 http://www.translational-medicine.com/content/10/S1/S6 PROCEEDINGS Open Access Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis Wei Wei1*, Hui Hu1, Haosheng Tan1, Louis WC Chow2, Adrian YS Yip2, Wings TY Loo2 From Organisation for Oncology and Translational Research (OOTR) 7th Annual Conference Hong Kong. 13-14 May 2011 Abstract Background: Axillary node staging plays an important role in the prognostic evaluation and planning of adjuvant treatment. Breast cancer stem cells, identified on the basis of CD44+CD24-/low expression, are associated with metastases and drug resistance. It is therefore important to investigate the proportion of CD44+CD24-/low breast cancer stem cells for the diagnosis of metastases in axillary nodes. Methods: Thirty-two ipsilateral axillary lymph nodes were collected from patients diagnosed with invasive breast cancer. Each lymph node (LN) was divided into two equals – one was examined by H&E staining, while the other was made into a single cell suspension to study the content of CD44+CD24-/low cells by flow cytometry (FCM). The relationship was investigated between the content of CD44+CD24-/low cells and metastases in axillary nodes which were confirmed by histology. Associations were tested using the chi-square test (linear-by-linear association), and the significance level was set at a value of p < 0.05. Results: In the 32 axillary nodes, the level of CD44+CD24-/low cells was determined to be between 0 and 18.4%: there was no presence of CD44+CD24-/low cells in 9 LNs, of which 2 had confirmed metastasis; there were less than 10% CD44+CD24-/low cells in 12 LNs, of which 6 had confirmed metastasis; and there were more than 10% CD44+CD24-/ low cells in 11 LNs, of which 9 had confirmed metastasis.
    [Show full text]
  • CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular
    Published OnlineFirst August 25, 2009; DOI: 10.1158/1078-0432.CCR-09-0151 Published Online First on August 25, 2009 as 10.1158/1078-0432.CCR-09-0151 Imaging, Diagnosis, Prognosis CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery Xin-Rong Yang,1 Yang Xu,1 Bin Yu,2 Jian Zhou,1 Jia-Chu Li,3 Shuang-Jian Qiu,1 Ying-Hong Shi,1 Xiao-Ying Wang,1 Zhi Dai,1 Guo-Ming Shi,1 Bin Wu,1 Li-Ming Wu,1 Guo-Huan Yang,1 Bo-Heng Zhang,1 Wen-Xin Qin,2 and Jia Fan1,4 Abstract Purpose: To investigate the role of CD24 in tumor invasion and prognostic significance in hepatocellular carcinoma (HCC). Experimental Design: CD24 expression was measured in stepwise metastatic HCC cell lines, tumor, peritumoral tissues, and normal liver tissues by quantitative real-time PCR and Western blot. The role of CD24 in HCC was investigated by CD24 depletion using small interfering RNA. Tumor tissue microarrays of 314 HCC patients who underwent resection between 1997 and 2000 were used to detect expression of CD24, β-catenin, and proliferating cell nuclear antigen. Prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. Results: CD24 was overexpressed in the highly metastatic HCC cell line and in tumor tissues of patients with recurrent HCC. Depletion of CD24 caused a notable decrease in cell proliferation, migration, and invasiveness in vitro. Univariate and multivariate anal- yses revealed that CD24 was a significant predictor for overall survival and relapse-free survival. CD24 expression was correlated with poor prognosis independent of α-feto- protein, tumor-node-metastasis stage, and Edmondson stage.
    [Show full text]
  • Correlation of CD44 and CD24 Expression with the Positive Response After Neoadjuvant Chemotherapy in Stage IIIB Breast Cancer Pa
    ORIGINAL ARTICLE Bali Medical Journal (Bali MedJ) 2021, Volume 10, Number 1: 99-102 P-ISSN.2089-1180, E-ISSN: 2302-2914 Correlation of CD44 and CD24 expression with the positive response after neoadjuvant Published by Bali Medical Journal chemotherapy in stage IIIB breast cancer patient at Dr. Saiful Anwar Hospital, Malang, Indonesia Muhammad Bachtiar Budianto1*, Artono Isharanto2, Andry Haris3 1Department of Oncology Surgery, ABSTRACT Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia Background: Breast cancer is a type of cancer due to abnormal cell growth of breast tissue. CD44 and CD24 is a potential 2 Department of Thoracic and target in breast cancer therapy. This study aims to evaluate the responsiveness of stage 3 breast cancer to chemotherapy by Cardiovascular Surgery, Faculty of measuring the expression levels of CD44 and CD24 molecules. Medicine, Universitas Brawijaya, Malang, Indonesia Methods: We conducted an observational study with pre-and –post-intervention or test research types. This study was 3General Surgery Resident, Faculty of performed on 49 Luminal Stadium IIIB subtype breast cancer patients who received 3 series of neoadjuvant chemotherapy at Medicine, Universitas Brawijaya, Malang, RSUD dr. Saiful Anwar Malang, immunohistochemical examination, and painting of tissue specimens from the biopsy results. Indonesia Data were analyzed using SPSS version 20 for Windows. Results: Based on the Paired t-test and discriminant analysis, there were no significant differences between CD44 and CD24 expression before and after chemotherapy (p=0.501 and p=0.097, respectively). Therefore, the results of the study prompt *Corresponding author: that the expression of CD44 and CD24 could not be a predictor of the chemotherapy response.
    [Show full text]
  • Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases
    cells Review Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases Ping Song * , Junqing An and Ming-Hui Zou Center for Molecular and Translational Medicine, Georgia State University, 157 Decatur Street SE, Atlanta, GA 30303, USA; [email protected] (J.A.); [email protected] (M.-H.Z.) * Correspondence: [email protected]; Tel.: +1-404-413-6636 Received: 29 January 2020; Accepted: 5 March 2020; Published: 10 March 2020 Abstract: Senescent cells are generally characterized by permanent cell cycle arrest, metabolic alteration and activation, and apoptotic resistance in multiple organs due to various stressors. Excessive accumulation of senescent cells in numerous tissues leads to multiple chronic diseases, tissue dysfunction, age-related diseases and organ ageing. Immune cells can remove senescent cells. Immunaging or impaired innate and adaptive immune responses by senescent cells result in persistent accumulation of various senescent cells. Although senolytics—drugs that selectively remove senescent cells by inducing their apoptosis—are recent hot topics and are making significant research progress, senescence immunotherapies using immune cell-mediated clearance of senescent cells are emerging and promising strategies to fight ageing and multiple chronic diseases. This short review provides an overview of the research progress to date concerning senescent cell-caused chronic diseases and tissue ageing, as well as the regulation of senescence by small-molecule drugs in clinical trials and different roles and regulation of immune cells in the elimination of senescent cells. Mounting evidence indicates that immunotherapy targeting senescent cells combats ageing and chronic diseases and subsequently extends the healthy lifespan. Keywords: cellular senescence; senescence immunotherapy; ageing; chronic disease; ageing markers 1.
    [Show full text]
  • Hoxa5, a Cell Fate Transition Regulator, Impedes Tumor Initiation and Progression in Breast Cancer
    HOXA5, A CELL FATE TRANSITION REGULATOR, IMPEDES TUMOR INITIATION AND PROGRESSION IN BREAST CANCER by Wei Wen Teo A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland November, 2015 ©2015 Wei Wen Teo All Rights Reserved Abstract This thesis focuses on understanding the biological functions of HOXA5 in mammary epithelial differentiation and breast cancer progression. Members of HOX cluster have long been associated with cellular differentiation. Nonetheless, how HOX genes drive differentiation in mammalian cells is poorly understood. The expression of HOXA5 is frequently deregulated in breast cancer, while higher HOXA5 expression predicts better relapse free survival in breast cancer patients. My research has demonstrated that depleting HOXA5, a key regulator during embryogenesis, increases cell plasticity and stemness in the human breast epithelial cell line, MCF10A. Comparison of MCF10A cells and HOXA5-depleted MCF10A cells by expression array analysis revealed HOXA5’s ability to regulate several traits of epithelial lineage, including E-cadherin and CD24. Analysis of the expression array by gene set enrichment analysis (GSEA) confirmed the negative correlation between epithelial traits and the transcriptome of HOXA5-depleted MCF10A cells. Using an inducible HOXA5- knockdown system, we demonstrated how HOXA5 depletion restrained state transition from CD24-/CD44+ to CD24+/CD44+ cells upon treatment of retinal. The increase of expression of adhesions proteins was, however, impeded when HOXA5 was simultaneously repressed. Failure of state transition upon depletion of HOXA5 resulted in increased ability for mammosphere formation. Furthermore, depleting HOXA5 in MCF10A-KRAS transformed cells reduced CD24+/CD44lo population and enhanced the ii self-renewal capacity of MCF10A-KRAS cells in culture.
    [Show full text]
  • Molecular and Clinical Dissection of CD24 Antibody Specificity by A
    Laboratory Investigation (2010) 90, 1102–1116 & 2010 USCAP, Inc All rights reserved 0023-6837/10 $32.00 Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis Glen Kristiansen1,6, Eda Machado2,6, Niko Bretz3, Christian Rupp3, Klaus-Ju¨rgen Winzer4, Anne-Kathleen Ko¨nig3, Gerhard Moldenhauer3, Frederik Marme´5, Julia Costa2 and Peter Altevogt3 CD24 is a small, highly glycosylated cell surface protein that is linked to the membrane through a glycosyl-phosphati- dylinositol anchor. It is overexpressed in many human carcinomas and its expression is linked to bad prognosis. Lately, lack or low expression of CD24 was used to identify tumor stem cells resulting in conflicting data on the usefulness of this marker. In many immunohistochemical studies, the mAb SN3b was used but the epitope and specificity of this antibody have never been thoroughly investigated. In other studies based mainly on cytofluorographic analysis, the mAb ML-5 was applied. In this study, we compared the epitope of mAb SN3b to the CD24 mAbs SWA-11 and ML-5 that both bind to the core protein of CD24. Using tissue microarrays and affinity-purified CD24 glycoforms, we observed only a partial overlap of SN3b and SWA11 reactivity. The mAb SN3b recognizes sialic acid most likely on O-linked glycans that can occur independently of the CD24 protein backbone. The SN3b epitope was not related to common sialylated cancer-associated glycan structures. Both SN3b epitope positive or negative CD24 glycoforms supported the binding of P-selectin and Siglec-5. In breast cancer, the SN3b reactivity was associated with bad prognosis, whereas SWA11 was not.
    [Show full text]
  • The Emerging Role of CD24 in Cancer Theranostics—A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond
    Journal of Personalized Medicine Review The Emerging Role of CD24 in Cancer Theranostics—A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond Katrin Kleinmanns 1,* , Vibeke Fosse 1, Line Bjørge 1,2 and Emmet McCormack 1,3,4 1 Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway; [email protected] (V.F.); [email protected] (L.B.); [email protected] (E.M.) 2 Department of Obstetrics and Gyneacology, Haukeland University Hospital, 5021 Bergen, Norway 3 Centre for Pharmacy, Department of Clinical Science, University of Bergen, Jonas Lies vei 65, 5021 Bergen, Norway 4 Department of Clinical Science, University of Bergen, Jonas Lies vei 65, 5021 Bergen, Norway * Correspondence: [email protected] Received: 10 November 2020; Accepted: 26 November 2020; Published: 27 November 2020 Abstract: Complete cytoreductive surgery is the cornerstone of the treatment of epithelial ovarian cancer (EOC). The application of fluorescence image-guided surgery (FIGS) allows for the increased intraoperative visualization and delineation of malignant lesions by using fluorescently labeled targeting biomarkers, thereby improving intraoperative guidance. CD24, a small glycophosphatidylinositol-anchored cell surface receptor, is overexpressed in approximately 70% of solid cancers, and has been proposed as a prognostic and therapeutic tumor-specific biomarker for EOC. Recently, preclinical studies have demonstrated the benefit of CD24-targeted contrast agents for non-invasive fluorescence imaging, as well as improved tumor resection by employing CD24-targeted FIGS in orthotopic patient-derived xenograft models of EOC. The successful detection of miniscule metastases denotes CD24 as a promising biomarker for the application of fluorescence-guided surgery in EOC patients.
    [Show full text]
  • Residual Breast Cancers After Conventional Therapy Display Mesenchymal As Well As Tumor-Initiating Features
    Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Chad J. Creightona,1, Xiaoxian Lia,1, Melissa Landisa,1, J. Michael Dixonb, Veronique M. Neumeisterc, Ashley Sjolundc, David L. Rimmc, Helen Wonga, Angel Rodrigueza, Jason I. Herschkowitza, Cheng Fand, Xiaomei Zhanga, Xiaping Hec, Anne Pavlicka, M. Carolina Gutierreza, Lorna Renshawb, Alexey A. Larionovb, Dana Faratianb, Susan G. Hilsenbecka, Charles M. Peroud, Michael T. Lewisa,2, Jeffrey M. Rosena,2, and Jenny C. Changa,2,3 aDepartment of Molecular and Cellular Biology, Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; bWestern General Hospital, Edinburgh EH4 2XU, United Kingdom; cYale University School of Medicine, New Haven, CT 06510; and dDepartments of Genetics and of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 Communicated by Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA, May 26, 2009 (received for review December 19, 2008) Some breast cancers have been shown to contain a small fraction of Global gene expression analyses have identified at least four ,cells characterized by CD44؉/CD24؊/low cell-surface antigen profile major subtypes of human breast cancers (luminal A/B, basal-like that have high tumor-initiating potential. In addition, breast cancer and ERBB2-enriched) (4, 5). More recently Herschkowitz et al. (6) cells propagated in vitro as mammospheres (MSs) have also been described another subtype, involving relatively uncommon breast shown to be enriched for cells capable of self-renewal. In this study, cancers, termed ‘‘claudin-low,’’ which are characterized by com- we have defined a gene expression signature common to both paratively high expression of mesenchymal markers such as vimen- CD44؉/CD24؊/low and MS-forming cells.
    [Show full text]
  • Cd24 in T Lymphocyte Homeostatic Proliferation And
    CD24 IN T LYMPHOCYTE HOMEOSTATIC PROLIFERATION AND AUTOIMMUNE DISEASE DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Ou Li, Bachelor of Medicine The Ohio State University 2005 Dissertation Committee: Yang Liu, Ph.D., Advisor Approved By Pan Zheng, M.D., Ph.D. W. James Waldman, Ph.D. _________________________________ Xuefeng Bai, M.D., Ph. D. Advisor Jianxin Gao, M.D., Ph.D. Department of Pathology ABSTRACT In this thesis, we show that CD24 can regulate naïve T cell homeostatic proliferation and autoimmune disease. The activation of T lymphocyte requires two signals from antigen presenting cells, peptide and self-MHC complex to TCR and co stimulatory signals. CD24, a glycosyl-phosphatidylinositol (GPI) arched glycoprotein, is an important co-stimulatory molecule. Although it is not essential for induction of T cell response, CD24 is required to express on T cells and for the induction of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). Here, we show that CD24 is essential for local clonal expansion and persistence of T cells after their migration into the CNS, and that expression of CD24 on either hematopoietic cells or non-hematopoietic antigen-presenting cells in the recipient is sufficient to confer susceptibility to EAE. At the same time, it is well established that T lymphocytes undergo homeostatic proliferation in lymphopenic environment. The homeostatic proliferation requires recognition of major histocompatibility complex on the host. Recent studies have demonstrated that co-stimulation, mediated by CD28, 4-1BB, and CD40, is not required for T cell homeostatic proliferation.
    [Show full text]